期刊文献+

固体脂微颗粒载药体系中稳定剂的作用和机理 被引量:1

Mechanism of Stabilizers in Solid Lipid Microparticles
下载PDF
导出
摘要 以硬脂精为载体材料,采用熔融-冷却法制备包载布洛芬的固体脂微颗粒(SLM),研究了不同稳定剂对SLM载药体系的稳定效果.实验结果表明聚乙烯醇(PVA)和卵磷脂/牛胆盐是制备硬脂精SLM的较好的稳定剂.进一步研究这两种稳定剂在布洛芬含量增大时对硬脂精SLM的稳定效果,发现当布洛芬含量达7%(质量分数,下同)时,以卵磷脂/牛胆盐为稳定剂的SLM体系开始发生聚集;而对于以PVA为稳定剂的SLM体系,当布洛芬含量增加到25%时,SLM体系仍能保持很好的稳定性.文中还基于对稳定剂分子特征以及载药体系微观结构的分析和介观模拟,从理论上解释了稳定剂的稳定作用和机理. The emulsion-congealing method was adopted to prepare ibuprofen-loaded solid lipid microparticles (SLM) with tristearin as the carrier. The stabilities of the SLM stabilized with different stabilizers were also investigated, proving that polyvinyl alcohol (PVA) and soy lecithin/bile salt are good stabilizers for the SLM system. The stabilities of the SLM stabilized with these two stabilizers at an increasing ibuprofen content were then investigated. Experimental results show that, at an ibuprofen mass fraction of 7% , the SLM system stabilized with soy lecithin/ bile salt begins to congregate, while the one stabilized with PVA remains stable even when ibuprofen mass fraction is up to 25%. The stabilizing mechanism of the stabilizers was finally interpreted based on the analysis and simulation of the molecular structure of the stabilizer and the microstructure of the drug carrier.
出处 《华南理工大学学报(自然科学版)》 EI CAS CSCD 北大核心 2006年第8期84-88,93,共6页 Journal of South China University of Technology(Natural Science Edition)
基金 国家自然科学基金资助项目(20376025 20476033) 国家杰出青年基金资助项目(20225620) 国家自然科学基金重点资助项目(20536020) 广东省自然科学基金资助项目(04020121)
关键词 固体脂微颗粒 稳定性 药物释放体系 布洛芬 solid lipid microparticle stability drug delivery system ibuprofen
  • 相关文献

参考文献10

  • 1Panyam J,Labhasetwar V.Biodegradable nanoparticles for drug and gene delivery to cells and tissue[J].Advanced Drug Delivery Reviews,2003,55:329-347.
  • 2Mehnert W,Mader K.Solid lipid nanoparticles production,characterization and applications[J].Advanced Drug Delivery Reviews,2001,42:165-196.
  • 3Gasco M R.Method for producing solid lipid microspheres having a narrow size distribution:US,188837[P].1993-10-05
  • 4Freitas C,Müller R H.Correlation between long-term stability of solid lipid nanoparticles and crystallinity of the lipid phase[J].European Journal of Pharmaceutics and Biopharmaceutics,1999,47:125-132.
  • 5Cortesi R,Esposito E,Luca G,et al.Production of lipospheres as carriers for bioactive compounds[J].Biomaterials,2002,23:2 283-2 294.
  • 6Zimmermann E,Müller R H.Electrolyte-and pH-stabilities of aqueous solid lipid nanoparticle dispersions in artificial gastrointestinal media[J].European Journal of Pharmaceutics and Biopharmaceutics,2001,52:203-210.
  • 7Venkateswarlu V,Manjunath K.Preparation characterization and in vitro release kinetics of clozapine solid lipid nanoparticles[J].Journal of Controlled Release,2004,95:627-638.
  • 8Mühlen A Z,Schwarz C,Mehnert W.Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism[J].European Journal of Pharmaceutics and Biopharmaceutics,1998,45:149-155.
  • 9Westesen K,Bunjes H,Koch M H J.Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential[J].Journal of Controlled Release,1997,48:223-236.
  • 10Westesen K,Siekmann B.Investigation of the gel formation of phospholipids-stabilized solid lipid nanoparticles[J].International Journal of Pharmaceutics,1997,151:35-45.

同被引文献11

  • 1Maheshwari M,Ketkar A R,Chauhan B,et al.Preparation and characterization of ibuprofen-cetyl alcohol beads by melt solidification technique:effect of variables[J].International Journal of Pharmaceutics,2003,261(1/2):57-67.
  • 2Hou D Z,Xie C S,Huang K J.The production and characteristics of solid lipid nanoparticles (SLNs)[J].Biomaterials,2003,24(10):1781-1785.
  • 3Mühlen A Z,Schwarz C,Mehnert W.Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism[J].European Journal of Pharmaceutics and Biopharmaceutics,1998,45(2):149-155.
  • 4Henrik K F,Henning G K,Morten P.Solid lipid microparticle formulations of the pyrethroid gamma-cyhalothrin-incompatibility of the lipid and the pyrethroid and biological properties of the formulations[J].Journal of Controlled Release,2003,86(2/3):243-252.
  • 5Gavini E,Sanna V,Sharma R,et al.Solid lipid microparticles(SLM) containing juniper oil as anti-acne topical carriers:preliminary studies[J].Pharmaceutical Development and Technology,2005,10(4):479-487.
  • 6Demirel M,Yazan Y,Muller R H,et al.Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro-and nanoparticles[J].Journal of Microencapsulation,2001,18(3):347-357.
  • 7Müller R H,Radtke M,Wissing S A.Nanostructured lipid matrices for improved microencapsulation of drugs[J].International Journal of Pharmaceutics,2002,242(1/2):121-128.
  • 8Hagemann J W.Crystallization and polymorphism of fats and fatty acids[M].New York:Marcel Dekker Inc,1988.
  • 9Freitas C,Müller R H.Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystalli-nity of the lipid phase[J].European Journal of Pharmaceutics and Biopharmaceutics,1999,47(2):125-132.
  • 10陈华兵,翁婷,常雪灵,杨亚江,杨祥良.布洛芬微乳的制备及其透皮吸收研究[J].中国药学杂志,2004,39(1):43-45. 被引量:43

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部